M&A

News

Taisho says $5bn management buyout will rev up business

Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi

News

Roche makes obesity play with $2.7bn deal to buy Carmot

Roche has agreed a deal to acquire US biotech Carmot Therapeutics that, if consummated, will thrust it into the increasingly competitive market for incretin-based therapie

News

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar

News

Boehringer buys cancer immunotherapy firm T3 for $507m

Germany’s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland.

News

MSD reaches $610m deal to buy lysosome biotech Caraway

MSD has agreed to pay up to $610 million to acquire Caraway Therapeutics, a Cambridge, Massachusetts biotech focusing on neurodegenerative disorders and rare diseases.

News

Digital health company BehaVR hits the merger trail again

Less than a year after joining with OxfordVR to create a specialist in digital therapeutics (DTx) for mental illnesses, BehaVR has expanded into the chronic pain category

Taisho says $5bn management buyout will rev up business

Roche makes obesity play with $2.7bn deal to buy Carmot

AbbVie agrees $10.1bn deal to buy ImmunoGen

Boehringer buys cancer immunotherapy firm T3 for $507m

MSD reaches $610m deal to buy lysosome biotech Caraway

Digital health company BehaVR hits the merger trail again

Roche's IgAN hopeful sefaxersen passes phase 3 test

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks